Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18576512 | 0.69 | PIK3C3 (0.30) | — | |
| SCHEMBL18896069 | 0.69 | LMNA (0.33) | LMNAMAPT | |
| SCHEMBL22813222 | 0.67 | — | — | |
| SCHEMBL8031111 | 0.67 | KMT2A (0.31) | — | |
| SCHEMBL24322549 | 0.65 | LMNA (0.37) | LMNAMAPT | |
| SCHEMBL24246510 | 0.65 | BRD4 (0.32) | LMNAMAPT | |
| SCHEMBL14660278 | 0.65 | CRBN (0.34) | LMNAMAPT | |
| SCHEMBL19749751 | 0.64 | LMNA (0.32) | LMNAMAPT | |
| SCHEMBL21482019 | 0.63 | P2RX7 (0.33) | — | |
| SCHEMBL20672077 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247993-B2 | Pyridone derivative, composition and use as antiviral drug thereof | JIANGXI CAISHI PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
| EP-3753936-A1 | PYRIDONE DERIVATIVE, COMPOSITION THEREOF AND APPLICATION THEREOF AS ANTI-INFLUENZA DRUG | Jiangxi Caishi Pharmaceutical Technology Co., Ltd. (CN) | 2020-12-23 | — | — | EP | disclosed |
| US-20200247812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | INTEGRAL BIOSCIENCES PRIVATE LTD (IN) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247993-B2 | Pyridone derivative, composition and use as antiviral drug thereof | PNP, POLB, POLA1 | LMNA 177/4885MAPT 3679/4885 |
| US-20200247812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ACVR1, ACVRL1, ALK | LMNA 1500/4885MAPT 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.